Header Logo

DOV KADMON

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Urology
Address7200 CAMBRIDGE
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA044274     (KADMON, DOV)Jul 1, 1986 - Jun 30, 1989
    NIH
    POLYAMINE BASED SCAN FOR METASTATIC PROSTATE CANCER
    Role: Principal Investigator
    K04CA001248     (KADMON, DOV)May 1, 1986 - Mar 31, 1989
    NIH
    POLYAMINE BASED SCAN FOR METASTATIC PROSTATE CANCER
    Role: Principal Investigator
    K04CA000931     (KADMON, DOV)Apr 15, 1984 - Mar 31, 1989
    NIH
    POLYAMINE BASED SCAN FOR METASTATIC PROSTATE CANCER
    Role: Principal Investigator
    R01CA034873     (KADMON, DOV)May 1, 1983 - Apr 30, 1986
    NIH
    POLYAMINE BASED SCAN FOR METASTATIC PROSTATE CANCER
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hinojosa-Gonz?lez DE, Saffati G, Kronstedt S, La T, Chiu C, Wahlstedt E, Jones JA, Kadmon D, Badal J, Taylor JM, Slawin JR. Comparison of peritoneal interposition flaps and sealants for prevention of lymphocele after robotic radical prostatectomy and pelvic lymph node dissection: a systematic review, meta-analysis, Bayesian network meta-analysis, and meta-regression. J Robot Surg. 2024 Apr 17; 18(1):177. PMID: 38630430.
      Citations:    Fields:    Translation:Humans
    2. Hinojosa-Gonzalez DE, Nolazco JI, Saffati G, Kronstedt S, Jones JA, Kadmon D, Badal J, Slawin JR, Hinojosa-Gonzalez DE, Nolazco JI, Saffati G, Kronstedt S, Jones JA, Kadmon D, Badal J, Slawin JR. Oncologic Outcome of the Extent of Pelvic Lymph Node Dissection During Radical Prostatectomy: A Systematic Review, Meta-analysis, and Network Analysis. Eur Urol Focus. 2024 Mar; 10(2):234-241. PMID: 38242825.
      Citations: 1     Fields:    Translation:Humans
    3. Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, Ragheb A, Frolov A, Michailidis G, Lee M, Kadmon D, Miles B, Smith C, Ittmann M, Rowley D, Sreekumar A, Creighton CJ, Ayala G. Influence of the neural microenvironment on prostate cancer. Prostate. 2018 Feb; 78(2):128-139. PMID: 29131367; PMCID: PMC5836952.
      Citations: 24     Fields:    Translation:Animals
    4. De Vivar AD, Sayeeduddin M, Rowley D, Cubilla A, Miles B, Kadmon D, Ayala G. Histologic features of stromogenic carcinoma of the prostate (carcinomas with reactive stroma grade 3). Hum Pathol. 2017 05; 63:202-211. PMID: 28315427.
      Citations: 7     Fields:    Translation:HumansCells
    5. Ding Y, He D, Florentin D, Frolov A, Hilsenbeck S, Ittmann M, Kadmon D, Miles B, Rowley D, Ayala G. Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11. PMID: 24097862; PMCID: PMC3898797.
      Citations: 22     Fields:    Translation:HumansCells
    6. Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann MM, Wheeler TM, Gee AP, Wang RF, Hayes TG. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr; 32(2):235-242. PMID: 23609828; PMCID: PMC4100683.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    7. Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82. PMID: 21933889; PMCID: PMC3865786.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    8. Ayala GE, Muezzinoglu B, Hammerich KH, Frolov A, Liu H, Scardino PT, Li R, Sayeeduddin M, Ittmann MM, Kadmon D, Miles BJ, Wheeler TM, Rowley DR. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87. PMID: 21224046; PMCID: PMC3069909.
      Citations: 27     Fields:    Translation:Humans
    9. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010 Mar; 13(1):6-11. PMID: 19581923; PMCID: PMC2887695.
      Citations: 44     Fields:    Translation:HumansCells
    10. Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni SD, Kadmon D, Thompson TC. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis. 2009; 12(3):301-9. PMID: 19104507.
      Citations: 3     Fields:    Translation:AnimalsCells
    11. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, Shine D, Kadmon D, Thompson T, Miles BJ, Ittmann MM, Rowley D. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603. PMID: 19047084.
      Citations: 122     Fields:    Translation:HumansAnimalsCells
    12. Ayala G, Yan J, Li R, Ding Y, Thompson TC, Mims MP, Hayes TG, MacDonnell V, Lynch RG, Frolov A, Miles BJ, Wheeler TM, Harper JW, Tsai MJ, Ittmann MM, Kadmon D. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8. PMID: 19010869; PMCID: PMC2820291.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    13. Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE. Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2008 Feb; 39(2):282-91. PMID: 18206496.
      Citations: 17     Fields:    
    14. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, Fattah el MA, Kadmon D, Thompson TC. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res. 2008 Feb 01; 68(3):731-9. PMID: 18245473.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    15. Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007 Dec 15; 110(12):2628-39. PMID: 17941029.
      Citations: 9     Fields:    Translation:Humans
    16. Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20. PMID: 17868773.
      Citations: 40     Fields:    Translation:HumansCells
    17. Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D, Thompson TC. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007 Nov; 38(11):1688-95. PMID: 17707459.
      Citations: 29     Fields:    Translation:HumansCells
    18. Teh BS, Bastasch MD, Mai WY, Kadmon D, Miles BJ, Butler EB. Preliminary report of the effect of high-dose adjuvant intensity modulated radiation therapy on the sural nerve graft for cavernosal nerve sacrifice after radical prostatectomy. Am J Clin Oncol. 2007 Aug; 30(4):395-400. PMID: 17762440.
      Citations:    Fields:    Translation:Humans
    19. Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Frolov A, Brenner MK, Kadmon D, Thompson TC. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27. PMID: 17627292.
      Citations: 5     Fields:    Translation:AnimalsCells
    20. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5. PMID: 16914574.
      Citations: 32     Fields:    Translation:Humans
    21. Teh BS, Bastasch MD, Mai WY, Kattan MW, Butler EB, Kadmon D. Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins. J Urol. 2006 Jun; 175(6):2097-101; discussion 2101-2. PMID: 16697811.
      Citations: 7     Fields:    Translation:Humans
    22. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, Wheeler TM, Miles BJ, Rauen K, Teh BS, Butler EB, Thompson TC, Kadmon D. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28. PMID: 16480930.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    23. Tetzlaff MT, Teh BS, Timme TL, Fujita T, Satoh T, Tabata K, Mai WY, Vlachaki MT, Amato RJ, Kadmon D, Miles BJ, Ayala G, Wheeler TM, Aguilar-Cordova E, Thompson TC, Butler EB. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36. PMID: 16417399.
      Citations: 4     Fields:    Translation:HumansAnimals
    24. Koh MS, Ittmann M, Kadmon D, Thompson TC, Leach FS. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006 Jan; 5(1):78-83. PMID: 16357515.
      Citations: 14     Fields:    Translation:Humans
    25. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005 Jun; 173(6):1923-5. PMID: 15879782.
      Citations: 23     Fields:    Translation:Humans
    26. van der Linden RR, Haagmans BL, Mongiat-Artus P, van Doornum GJ, Kraaij R, Kadmon D, Aguilar-Cordova E, Osterhaus AD, van der Kwast TH, Bangma CH. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol. 2005 Jul; 48(1):153-61. PMID: 15967266.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    27. Karakiewicz P, Shariat SF, Naderi A, Kadmon D, Slawin KM. Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. Urology. 2005 Jan; 65(1):131-5. PMID: 15667878.
      Citations: 3     Fields:    Translation:Humans
    28. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18. PMID: 15724144.
      Citations: 54     Fields:    Translation:HumansCells
    29. Canto EI, Singh H, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol. 2004 Sep; 172(3):900-4. PMID: 15310993.
      Citations: 8     Fields:    Translation:Humans
    30. Satoh T, Teh BS, Timme TL, Mai WY, Gdor Y, Kusaka N, Fujita T, Pramudji CK, Vlachaki MT, Ayala G, Wheeler T, Amato R, Miles BJ, Kadmon D, Butler EB, Thompson TC. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71. PMID: 15145177.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    31. Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology. 2004 May; 63(5):905-10; discussion 910-1. PMID: 15134977.
      Citations: 18     Fields:    Translation:Humans
    32. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol. 2004 May; 171(5):1850-4. PMID: 15076292.
      Citations: 28     Fields:    Translation:Humans
    33. Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9. PMID: 15050332.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    34. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol. 2004 Mar; 171(3):1089-92. PMID: 14767277.
      Citations: 29     Fields:    Translation:Humans
    35. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol. 2004 Jan; 171(1):204-9. PMID: 14665877.
      Citations: 6     Fields:    Translation:Humans
    36. Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N, Tian W, Ren C, Wang H, Kadmon D, Cai WW, Chinault AC, Boone TB, Bradley A, Thompson TC. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol. 2003 Apr; 162(4):1241-8. PMID: 12651616; PMCID: PMC1851223.
      Citations: 38     Fields:    Translation:Animals
    37. Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC. Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003 Apr; 4(3):251-61. PMID: 12643475.
      Citations: 3     Fields:    Translation:HumansAnimals
    38. Mouraviev V, Li L, Tahir SA, Yang G, Timme TM, Goltsov A, Ren C, Satoh T, Wheeler TM, Ittmann MM, Miles BJ, Amato RJ, Kadmon D, Thompson TC. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96. PMID: 12352463.
      Citations: 16     Fields:    Translation:HumansAnimals
    39. Bastasch MD, Teh BS, Mai WY, Carpenter LS, Lu HH, Chiu JK, Woo SY, Grant WH, Miles BJ, Kadmon D, Butler EB. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function. Int J Radiat Oncol Biol Phys. 2002 Sep 01; 54(1):101-6. PMID: 12182979.
      Citations: 5     Fields:    Translation:Humans
    40. Gdor Y, Timme TL, Miles BJ, Kadmon D, Thompson TC. Gene therapy for prostate cancer. Expert Rev Anticancer Ther. 2002 Jun; 2(3):309-21. PMID: 12113054.
      Citations: 1     Fields:    Translation:HumansCells
    41. Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GK, Schmidt J, Taylor AM, Lee M, Waldstreicher J, Pless Study Group. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002 May; 167(5):2105-8. PMID: 11956450.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    42. Teh BS, Aguilar-Cordova E, Vlachaki MT, Aguilar L, Mai WY, Caillouet J, Davis M, Miles B, Kadmon D, Ayala G, Lu HH, Chiu JK, Carpenter LS, Woo SY, Grant WH, Wheeler T, Thompson TC, Butler EB. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66. PMID: 12401909.
      Citations: 8     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    43. Kadmon D. Radiation therapy after radical prostatectomy: strike early, strike hard! The case for adjuvant radiation therapy. Rev Urol. 2002; 4(2):87-9. PMID: 16985660; PMCID: PMC1475975.
      Citations:    
    44. Kim ED, Nath R, Slawin KM, Kadmon D, Miles BJ, Scardino PT. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology. 2001 Dec; 58(6):983-7. PMID: 11744473.
      Citations: 15     Fields:    Translation:Humans
    45. Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, Adler HL, Kernen K, Pramudji CK, Satoh T, Gdor Y, Ren C, Ayala G, Wheeler TM, Butler EB, Kadmon D, Thompson TC. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67. PMID: 11686937.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    46. Teh BS, Aguilar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, Miles B, Kadmon D, Mai WY, Caillouet J, Davis M, Ayala G, Wheeler T, Brady J, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Butler EB. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13. PMID: 11597799.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    47. Kim ED, Nath R, Kadmon D, Lipshultz LI, Miles BJ, Slawin KM, Tang HY, Wheeler T, Scardino PT. Bilateral nerve graft during radical retropubic prostatectomy: 1-year followup. J Urol. 2001 Jun; 165(6 Pt 1):1950-6. PMID: 11371887.
      Citations: 6     Fields:    Translation:Humans
    48. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, Slawin KM. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001 May; 165(5):1554-9. PMID: 11342916.
      Citations: 48     Fields:    Translation:Humans
    49. Thompson TC, Timme TL, Ebara S, Satoh T, Yang G, Wang J, Miles BJ, Ayala G, Wheeler TM, Kadmon D. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95. PMID: 11727520.
      Citations: 1     Fields:    Translation:HumansAnimals
    50. Sukin SW, Chhikara M, Zhu X, Ayala G, Aguilar LK, O'Brian Smith E, Miles BJ, Thompson TC, Kadmon D, Aguilar-Cordova E. In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther. 2001 Apr; 3(4):500-6. PMID: 11319910.
      Citations: 3     Fields:    Translation:AnimalsCells
    51. Kim ED, Scardino PT, Kadmon D, Slawin K, Nath RK. Interposition sural nerve grafting during radical retropubic prostatectomy. Urology. 2001 Feb; 57(2):211-6. PMID: 11182323.
      Citations: 5     Fields:    Translation:HumansAnimals
    52. Shalev M, Thompson TC, Kadmon D, Ayala G, Kernen K, Miles BJ. Gene therapy for prostate cancer. Urology. 2001 Jan; 57(1):8-16. PMID: 11164134.
      Citations: 2     Fields:    Translation:HumansCells
    53. Thaller C, Shalev M, Frolov A, Eichele G, Thompson TC, Williams RH, Dillioglugil O, Kadmon D. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol. 2000 Nov 15; 18(22):3804-8. PMID: 11078493.
      Citations: 4     Fields:    Translation:HumansAnimalsCTClinical Trials
    54. Shalev M, Thompson TC, Frolov A, Lippman SM, Hong WK, Fritsche H, Kadmon D. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res. 2000 Oct; 6(10):3845-9. PMID: 11051228.
      Citations: 1     Fields:    Translation:Humans
    55. Ayala G, Wheeler TM, Shalev M, Thompson TC, Miles B, Aguilar-Cordova E, Chakraborty S, Kadmon D. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70. PMID: 10923926.
      Citations: 5     Fields:    Translation:HumansCells
    56. Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT, Miles BJ. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 2000 Jun; 163(6):1747-50. PMID: 10799174.
      Citations: 24     Fields:    Translation:HumansCells
    57. Smith VC, Edwards RA, Jorgensen JL, Goldfarb RA, Kadmon D, Cagle P, Truong LD. Unilocular retroperitoneal cyst of mesothelial origin presenting as a renal mass. Arch Pathol Lab Med. 2000 May; 124(5):766-9. PMID: 10782166.
      Citations: 1     Fields:    Translation:Humans
    58. Shalev M, Miles BJ, Thompson TC, Ayala G, Butler EB, Aguilar-Cordova E, Kadmon D. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene. World J Urol. 2000 Apr; 18(2):125-9. PMID: 10854147.
      Citations: 1     Fields:    Translation:HumansCells
    59. Kadmon D. Beyond prostate specific antigen--markers for prostate cancer for the 21st Century. J Urol. 2000 Mar; 163(3):828. PMID: 10687986.
      Citations:    Fields:    Translation:Humans
    60. Lotan Y, Xu XC, Shalev M, Lotan R, Williams R, Wheeler TM, Thompson TC, Kadmon D. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol. 2000 Jan; 18(1):116-21. PMID: 10623701.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    61. Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C, Ji X, Lee HM, Sehgal I, Anzano M, Sporn MB, Thompson TC. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis. 2000; 18(5):429-38. PMID: 11467776.
      Citations: 11     Fields:    Translation:AnimalsCells
    62. Smith CP, Sharma A, Ayala G, Cagle P, Kadmon D. Solitary pulmonary metastasis from prostate cancer. J Urol. 1999 Dec; 162(6):2102. PMID: 10569587.
      Citations: 13     Fields:    Translation:Humans
    63. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, Hudson P, Jackson CL, Romas NA, Patterson L, Cook TJ, Waldstreicher J. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998 Aug; 52(2):195-201; discussion 201-2. PMID: 9697781.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    64. Leis PF, Stevens KR, Baer SC, Kadmon D, Goldberg LH, Wang XJ. A c-rasHa mutation in the metastasis of a human papillomavirus (HPV)-18 positive penile squamous cell carcinoma suggests a cooperative effect between HPV-18 and c-rasHa activation in malignant progression. Cancer. 1998 Jul 01; 83(1):122-9. PMID: 9655301.
      Citations: 5     Fields:    Translation:HumansCells
    65. Sutton MA, Watkins HL, Green LK, Kadmon D. Intracranial metastases as the first manifestation of prostate cancer. Urology. 1996 Nov; 48(5):789-93. PMID: 8911530.
      Citations: 18     Fields:    Translation:Humans
    66. Kadmon D, Weinberg AD, Williams RH, Pavlik VN, Cooper P, Migliore PJ. Pitfalls in interpreting prostate specific antigen velocity. J Urol. 1996 May; 155(5):1655-7. PMID: 8627846.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    67. Timme TL, Yang G, Rogers E, Kadmon D, Morganstern JP, Park SH, Thompson TC. Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest. 1996 Apr; 74(4):747-60. PMID: 8606485.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    68. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene. 1995 Mar 02; 10(5):869-79. PMID: 7534899.
      Citations: 17     Fields:    Translation:AnimalsCells
    69. Timme TL, Truong LD, Slawin KM, Kadmon D, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech. 1995 Mar 01; 30(4):333-41. PMID: 7541677.
      Citations: 5     Fields:    Translation:Animals
    70. Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, DeKernion J, Rajfer J, Boake R, Crawford D, et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995 Mar; 45(3):491-7. PMID: 7533461.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    71. Timme TL, Yang G, Truong LD, Kadmon D, Park SH, Thompson TC. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol. 1995; 13(6):324-8. PMID: 9116750.
      Citations: 1     Fields:    Translation:HumansAnimals
    72. Feeney D, Quesada ET, Sirbasku DM, Kadmon D. Transitional cell carcinoma in a tuberculous kidney: case report and review of the literature. J Urol. 1994 Apr; 151(4):989-91. PMID: 8126846.
      Citations: 5     Fields:    Translation:Humans
    73. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology. 1994 Mar; 134(3):1039-45. PMID: 8119140.
      Citations: 12     Fields:    Translation:Animals
    74. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 1993 Oct 01; 53(19):4461-5. PMID: 8402613.
      Citations: 11     Fields:    Translation:AnimalsCells
    75. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transgenic models for the study of prostate cancer. Cancer. 1993 Feb 01; 71(3 Suppl):1165-71. PMID: 8428340.
      Citations: 4     Fields:    Translation:Animals
    76. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol. 1993 Jan; 24(1):4-9. PMID: 7678092.
      Citations: 25     Fields:    Translation:HumansCells
    77. Thompson TC, Timme TL, Kadmon D, Park SH, Egawa S, Yoshida K. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog. 1993; 7(3):165-79. PMID: 8489712.
      Citations: 10     Fields:    Translation:AnimalsCells
    78. Thompson TC, Egawa S, Kadmon D, Miller GJ, Timme TL, Scardino PT, Park SH. Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. J Steroid Biochem Mol Biol. 1992 Sep; 43(1-3):79-85. PMID: 1525069.
      Citations: 4     Fields:    Translation:AnimalsCells
    79. Kadmon D. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO). J Cell Biochem Suppl. 1992; 16H:122-7. PMID: 1289667.
      Citations: 7     Fields:    Translation:HumansAnimals
    80. Egawa S, Kadmon D, Miller GJ, Scardino PT, Thompson TC. Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol Carcinog. 1992; 5(1):52-61. PMID: 1543541.
      Citations: 3     Fields:    Translation:AnimalsCells
    81. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992; 16H:54-61. PMID: 1289674.
      Citations: 15     Fields:    Translation:HumansAnimals
    82. Moss JT, Kadmon D. BCG and the treatment of superficial bladder cancer. DICP. 1991 Dec; 25(12):1355-67. PMID: 1815434.
      Citations: 4     Translation:Humans
    83. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol. 1991 Aug; 146(2):358-61. PMID: 1856931.
      Citations: 16     Fields:    Translation:Humans
    84. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC. Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol. 1991 Apr; 5(4):503-13. PMID: 1922083.
      Citations: 11     Fields:    Translation:Animals
    85. Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH. Experimental oncogene induced prostate cancer. Cancer Surv. 1991; 11:55-71. PMID: 1726789.
      Citations: 2     Fields:    Translation:Animals
    86. Hwang DR, Mathias CJ, Welch MJ, McGuire AH, Kadmon D. Imaging prostate derived tumors with PET and N-(3-[18F]fluoropropyl)putrescine. Int J Rad Appl Instrum B. 1990; 17(6):525-32. PMID: 2254090.
      Citations: 3     Fields:    Translation:HumansAnimals
    87. Hwang DR, Lang LX, Mathias CJ, Kadmon D, Welch MJ. N-3-[18F]fluoropropylputrescine as potential PET imaging agent for prostate and prostate derived tumors. J Nucl Med. 1989 Jul; 30(7):1205-10. PMID: 2500502.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    88. Shabsigh R, Lerner S, Fishman IJ, Kadmon D. The role of transrectal ultrasonography in the diagnosis and management of prostatic and seminal vesicle cysts. J Urol. 1989 May; 141(5):1206-9. PMID: 2651723.
      Citations: 7     Fields:    Translation:Humans
    89. Heston WD, Kadmon D. alpha-Difluoromethylornithine enhancement of 14C-putrescine uptake by an androgen-dependent prostatic tumor. J Urol. 1986 Oct; 136(4):944-8. PMID: 3093695.
      Citations:    Fields:    Translation:Animals
    90. Kadmon D, Ling D, Lee JK. Percutaneous drainage of prostatic abscesses. J Urol. 1986 Jun; 135(6):1259-60. PMID: 3520019.
      Citations: 4     Fields:    Translation:Humans
    91. Kavoussi LR, Levine SR, Kadmon D, Fair WR. Regression of metastatic renal cell carcinoma: a case report and literature review. J Urol. 1986 May; 135(5):1005-7. PMID: 3959224.
      Citations: 4     Fields:    Translation:Humans
    92. Hwang DR, Jerabek PA, Kadmon D, Kilbourn MR, Patrick TB, Welch MJ. 2-[18F]fluoroputrescine: preparation, biodistribution, and mechanism of defluorination. Int J Rad Appl Instrum A. 1986; 37(7):607-12. PMID: 3021663.
      Citations: 1     Fields:    Translation:Animals
    93. Jerabek PA, Dence CS, Kilbourn MR, Welch MJ, Kadmon D. Synthesis and uptake of no-carrier-added 1-[11C]putrescine into rat prostate. Int J Nucl Med Biol. 1985; 12(5):349-52. PMID: 3833820.
      Citations: 1     Fields:    Translation:Animals
    94. Kadmon D, Mahle C, Heston WD, Hahn DA. Effect of estrogen and androgen administration on alpha-difluoromethylornithine-enhanced putrescine uptake by the rat prostate. Prostate. 1985; 6(4):343-9. PMID: 3937149.
      Citations: 1     Fields:    Translation:Animals
    95. Ratliff TL, Kadmon D, Shapiro A, Jacobs AJ, Heston WD. Inhibition of mouse bladder tumor proliferation by murine interferon-gamma and its synergism with interferon-beta. Cancer Res. 1984 Oct; 44(10):4377-81. PMID: 6432311.
      Citations: 2     Fields:    Translation:AnimalsCells
    96. Heston WD, Kadmon D, Covey DF, Fair WR. Differential effect of alpha-difluoromethylornithine on the in vivo uptake of 14C-labeled polyamines and methylglyoxal bis(guanylhydrazone) by a rat prostate-derived tumor. Cancer Res. 1984 Mar; 44(3):1034-40. PMID: 6420052.
      Citations: 5     Fields:    Translation:AnimalsCells
    97. Kadmon D, Heston WD, Lazan DW, Fair WR. Difluoromethylornithine enhancement of putrescine uptake into the prostate: concise communication. J Nucl Med. 1982 Nov; 23(11):998-1002. PMID: 6813433.
      Citations: 4     Fields:    Translation:Animals
    98. Shapiro A, Kadmon D, Catalona WJ, Ratliff TL. Immunotherapy of superficial bladder cancer. J Urol. 1982 Nov; 128(5):891-4. PMID: 6184490.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    99. Fair WR, Heston WD, Kadmon D, Crane DB, Catalona WJ, Ladenson JH, McDonald JM, Noll BW, Harvey G. Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. J Urol. 1982 Oct; 128(4):735-8. PMID: 6183457.
      Citations: 3     Fields:    Translation:Humans
    100. Kadmon D, Heston WD, Fair WR. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol. 1982 Jun; 127(6):1238-42. PMID: 7087045.
      Citations: 14     Fields:    Translation:Animals
    101. Heston WD, Kadmon D, Fair WR. Growth inhibition of a prostate tumor by alpha-difluoromethylornithine and by cyclophosphamide. Cancer Lett. 1982 May-Jun; 16(1):71-79. PMID: 6811130.
      Citations: 1     Fields:    Translation:AnimalsCells
    102. Lazan DW, Heston WD, Kadmon D, Fair WR. Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1,2-bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res. 1982 Apr; 42(4):1390-4. PMID: 7060012.
      Citations: 3     Fields:    Translation:Animals
    103. Heston WD, Kadmon D, Lazan DW, Fair WR. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine. Prostate. 1982; 3(4):383-9. PMID: 6812032.
      Citations: 3     Fields:    Translation:AnimalsCells
    104. Heston WD, Kadmon D, Fair WR. Effect of high dose diethylstilbestrol and ICRF-159 on the growth and metastases of the R3327 MAT-LyLu prostate-derived tumor. Cancer Lett. 1981 Jul; 13(2):139-45. PMID: 7306951.
      Citations: 1     Fields:    Translation:Animals
    105. Kadmon D, Heston WD, Fair WR. Effect of surgery and adjuvant chemotherapy on the R3327 MAT-Ly Lu tumor. Prostate. 1981; 2(3):299-307. PMID: 7301657.
      Citations: 1     Fields:    Translation:Animals
    106. Catalona WJ, Kadmon D, Crane DB. Effect of mini-dose heparin on lymphocele formation following extraperitoneal pelvic lymphadenectomy. J Urol. 1980 Jun; 123(6):890-2. PMID: 7382008.
      Citations: 11     Fields:    Translation:Humans
    107. Catalona WJ, Kadmon D, Martin SA. Surgical considerations in treatment of intraductal carcinoma of the prostate. J Urol. 1978 Aug; 120(2):259-61. PMID: 209223.
      Citations: 4     Fields:    Translation:Humans
    108. Kadmon D, Rozin R, Merhav A, Pappu J. [Multiple giant hepatic hemangiomas]. Harefuah. 1976 May 16; 90(10):470-3. PMID: 964729.
      Citations:    Fields:    Translation:Humans
    KADMON's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (402)
    Explore
    _
    Co-Authors (25)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _